Hualan Biological EngineeringInc (002007) - Total Assets
Based on the latest financial reports, Hualan Biological EngineeringInc (002007) holds total assets worth CN¥16.27 Billion CNY (≈ $2.38 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Hualan Biological EngineeringInc shareholders equity for net asset value and shareholders' equity analysis.
Hualan Biological EngineeringInc - Total Assets Trend (2001–2024)
This chart illustrates how Hualan Biological EngineeringInc's total assets have evolved over time, based on quarterly financial data.
Hualan Biological EngineeringInc - Asset Composition Analysis
Current Asset Composition (December 2024)
Hualan Biological EngineeringInc's total assets of CN¥16.27 Billion consist of 59.0% current assets and 41.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.4% |
| Accounts Receivable | CN¥2.07 Billion | 12.7% |
| Inventory | CN¥2.03 Billion | 12.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥346.83 Million | 2.1% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2001–2024)
This chart illustrates how Hualan Biological EngineeringInc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Hualan Biological EngineeringInc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hualan Biological EngineeringInc's current assets represent 59.0% of total assets in 2024, a decrease from 63.9% in 2001.
- Cash Position: Cash and equivalents constituted 8.4% of total assets in 2024, down from 13.5% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 6.0% in 2001.
- Asset Diversification: The largest asset category is accounts receivable at 12.7% of total assets.
Hualan Biological EngineeringInc Competitors by Total Assets
Key competitors of Hualan Biological EngineeringInc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Hualan Biological EngineeringInc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.43 | 4.05 | 3.92 |
| Quick Ratio | 2.65 | 3.21 | 3.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥7.12 Billion | CN¥6.98 Billion | CN¥5.60 Billion |
Hualan Biological EngineeringInc - Advanced Valuation Insights
This section examines the relationship between Hualan Biological EngineeringInc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.46 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | 1.3% |
| Total Assets | CN¥16.31 Billion |
| Market Capitalization | $3.86 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Hualan Biological EngineeringInc's assets below their book value (0.24x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Hualan Biological EngineeringInc's assets grew by 1.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Hualan Biological EngineeringInc (2001–2024)
The table below shows the annual total assets of Hualan Biological EngineeringInc from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥16.31 Billion ≈ $2.39 Billion |
+1.27% |
| 2023-12-31 | CN¥16.11 Billion ≈ $2.36 Billion |
+9.26% |
| 2022-12-31 | CN¥14.74 Billion ≈ $2.16 Billion |
+27.77% |
| 2021-12-31 | CN¥11.54 Billion ≈ $1.69 Billion |
+14.93% |
| 2020-12-31 | CN¥10.04 Billion ≈ $1.47 Billion |
+32.38% |
| 2019-12-31 | CN¥7.58 Billion ≈ $1.11 Billion |
+16.79% |
| 2018-12-31 | CN¥6.49 Billion ≈ $950.14 Million |
+24.40% |
| 2017-12-31 | CN¥5.22 Billion ≈ $763.75 Million |
+12.23% |
| 2016-12-31 | CN¥4.65 Billion ≈ $680.51 Million |
+15.64% |
| 2015-12-31 | CN¥4.02 Billion ≈ $588.47 Million |
+6.68% |
| 2014-12-31 | CN¥3.77 Billion ≈ $551.62 Million |
+3.47% |
| 2013-12-31 | CN¥3.64 Billion ≈ $533.13 Million |
+22.97% |
| 2012-12-31 | CN¥2.96 Billion ≈ $433.53 Million |
+8.33% |
| 2011-12-31 | CN¥2.73 Billion ≈ $400.21 Million |
+6.18% |
| 2010-12-31 | CN¥2.58 Billion ≈ $376.93 Million |
+28.04% |
| 2009-12-31 | CN¥2.01 Billion ≈ $294.38 Million |
+59.46% |
| 2008-12-31 | CN¥1.26 Billion ≈ $184.61 Million |
+31.66% |
| 2007-12-31 | CN¥958.23 Million ≈ $140.22 Million |
+17.43% |
| 2006-12-31 | CN¥815.97 Million ≈ $119.40 Million |
+16.57% |
| 2005-12-31 | CN¥699.99 Million ≈ $102.43 Million |
+8.69% |
| 2004-12-31 | CN¥644.01 Million ≈ $94.24 Million |
+84.78% |
| 2003-12-31 | CN¥348.52 Million ≈ $51.00 Million |
+44.28% |
| 2002-12-31 | CN¥241.56 Million ≈ $35.35 Million |
+23.81% |
| 2001-12-31 | CN¥195.12 Million ≈ $28.55 Million |
-- |
About Hualan Biological EngineeringInc
Hualan Biological Engineering Inc. researches, develops, produces, and commercializes blood products, vaccines, and genetic engineering products in China and internationally. The company offers human serum albumin to treat blood loss trauma, shock caused by burns, intracranial pressure and persistent, liver cirrhosis, and kidney disease; edema for hypoproteinemia, neonatal hyperbilirubinemia, car… Read more